China Shineway FY26 H1 profit drops 23.7% to RMB 469.16 million; revenue falls 28.5% to RMB 1.18 billion

• China Shineway Pharmaceutical posted profit of RMB 469.16 million, down 23.7%, as earnings per share fell 23.5% to RMB 0.62.
• Turnover slid 28.5% to RMB 1.18 billion, hit by medical insurance cost control, centralized procurement, weak demand, and channel destocking.
• Gross margin narrowed 2.3 percentage points to 69.9% on price cuts, lower sales volume, and persistently high production costs.
• Injection sales dropped 43.4% to RMB 319.92 million, while oral products fell 20.8% to RMB 861.16 million, remaining 72.9% of sales.
• Declared a second interim dividend of RMB 0.80 per share, payable Sept. 25, with R&D spending rising to 5.7% of turnover.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Shineway Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260827-12301587), on August 27, 2026, and is solely responsible for the information contained therein.